WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H531326
CAS#: 1527475-61-1
Description: PFE-360, also known asd PF-06685360, is a potent and selective inhibitor of LRRK2 kinase.
Hodoodo Cat#: H531326
Name: PFE-360
CAS#: 1527475-61-1
Chemical Formula: C16H16N6O
Exact Mass: 308.14
Molecular Weight: 308.345
Elemental Analysis: C, 62.32; H, 5.23; N, 27.26; O, 5.19
Synonym: PFE-360; PFE 360; PFE360; PF-06685360; PF06685360; PF 06685360; PF-6685360; PF6685360; PF 6685360;
IUPAC/Chemical Name: 1-Methyl-4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1H-pyrrole-2-carbonitrile
InChi Key: IYQTYHISVSPMSU-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H16N6O/c1-21-9-11(6-12(21)7-17)13-8-18-15-14(13)16(20-10-19-15)22-2-4-23-5-3-22/h6,8-10H,2-5H2,1H3,(H,18,19,20)
SMILES Code: N#CC1=CC(C2=CNC3=NC=NC(N4CCOCC4)=C32)=CN1C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 308.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Andersen MA, Christensen KV, Badolo L, Smith GP, Jeggo R, Jensen PH, Andersen KJ, Sotty F. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation. Neurobiol Dis. 2018 Aug;116:13-27. doi: 10.1016/j.nbd.2018.04.011. Epub 2018 Apr 20. PubMed PMID: 29680709.
2: Andersen MA, Wegener KM, Larsen S, Badolo L, Smith GP, Jeggo R, Jensen PH, Sotty F, Christensen KV, Thougaard A. PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology. 2018 Feb 15;395:15-22. doi: 10.1016/j.tox.2018.01.003. Epub 2018 Jan 4. PubMed PMID: 29307545.